The DOI matches its Crossref record.
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin
Abstract
The frequency of poor metabolizers of debrisoquin was low and similar in four different native Chinese nationalities. In a total sample of 695 Chinese subjects, only seven (1.01%) had a urinary ratio between debrisoquin and 4-hydroxydebrisoquin greater than 12.6, which is the antimode between poor metabolizers and extensive metabolizers in white populations. This is significantly lower than the 6.82% found in 1011 white Swedish healthy subjects (p less than 0.0001). Admixture analysis indicated the occurrence of two distributions within extensive metabolizers among both Chinese and white subjects. The mean of the distribution of metabolic ratios among Chinese extensive metabolizers was shifted toward higher values compared with Swedish extensive metabolizers (p less than 0.01). The frequency of poor metabolizers of S-mephenytoin was higher in 137 Chinese (14.6%) than in 488 Swedish (3.3%) subjects (p less than 0.0001). Our findings imply that drugs metabolized by these two polymorphic hydroxylases should be prescribed in different dosages to Chinese and white subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Weinshilboum, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020021 · Cited by 1,031
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
Inhibition and Induction of Cytochrome P450 and the Clinical Implications
Lin, J. H., & Lu, A. Y. H. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835050-00003 · Cited by 829
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype
Gaedigk, A., Simon, S., Pearce, R., Bradford, L., Kennedy, M., & Leeder, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100406 · Cited by 779
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants
Bradford, L. D. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.2.229 · Cited by 773
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part I
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318030-000000000-00000 · Cited by 756
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Smith, H. S. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60750-7 · Cited by 696
Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., Sjöqvist, F., & Ingelman-Sundberg, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11825 · Cited by 644
Self-citationMolecular Basis of Ethnic Differences in Drug Disposition and Response
Xie, H.-G., Kim, R. B., Wood, A. J., & Stein, C. M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.815 · Cited by 600
Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs
Bertilsson, L., Dahl, M., Dalén, P., & Al‐Shurbaji, A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01548.x · Cited by 579
Self-citationRitonavir: Clinical Pharmacokinetics and Interactions with Other Anti-HIV Agents
Hsu, A., Granneman, G. R., & Bertz, R. J. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835040-00002 · Cited by 483
A Major Role for CYP2A6 in Nicotine C-Oxidation by Human Liver Microsomes
Messina, E. S., Tyndale, R. F., & Sellers, E. M. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36947-2 · Cited by 453
Bertilsson, L. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529030-00005 · Cited by 432
Self-citationIshizaki, & Horai (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00022.x · Cited by 428
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Gardiner, S. J., & Begg, E. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.6 · Cited by 406
Pharmacogenomics: bench to bedside
Weinshilboum, R., & Wang, L. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1497 · Cited by 320
Wormhoudt, L. W., Commandeur, J. N. M., & Vermeulen, N. P. E. (1999) · Critical Reviews in Toxicology · doi:10.1080/10408449991349186 · Cited by 302
Pharmacokinetics of Haloperidol
Froemming, J. S., Lam, Y. W. F., Jann, M. W., & Davis, C. M. (1989) · Clinical Pharmacokinetics · doi:10.2165/00003088-198917060-00004 · Cited by 291
Clinical Pharmacokinetics and Metabolism of Chloroquine: Focus on Recent Advancements
Ducharme, J., & Farinotti, R. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631040-00003 · Cited by 289
10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes*
Dalén, P., Dahl, M.-L., Ruiz, M. L. B., Nordin, J., & Bertilsson, L. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90040-6 · Cited by 285
Self-citationGender-related differences in pharmacokinetics and their clinical significance
Tanaka, E. (1999) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1999.00246.x · Cited by 281
Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide
Tamargo, J., Le Heuzey, J.-Y., & Mabo, P. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1832-0 · Cited by 276
Recent Advances: the Cytochrome P450 Enzymes
Slaughter, R. L., & Edwards, D. J. (1995) · Annals of Pharmacotherapy · doi:10.1177/106002809502900612 · Cited by 274
Goh, B.-C., Lee, S.-C., Wang, L.-Z., Fan, L., Guo, J.-Y., Lamba, J., Schuetz, E., Lim, R., Lim, H.-L., Ong, A.-B., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.025 · Cited by 270
Hasler, J. A., Estabrook, R., Murray, M., Pikuleva, I., Waterman, M., Capdevila, J., Holla, V., Helvig, C., Falck, J. R., Farrell, G., et al. (1999) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(99)00005-9 · Cited by 267
L??tsch, J., Skarke, C., Liefhold, J., & Geisslinger, G. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443140-00003 · Cited by 256
Sex-specific differences in CYP450 isoforms in humans
Scandlyn, M. J., Stuart, E. C., & Rosengren, R. J. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.4.413 · Cited by 199
Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
Wang, J., Liu, Z., Wang, W., Chen, X., Shu, Y., He, N., & Zhou, H. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.116513 · Cited by 147
Ito, T., Kato, M., Chiba, K., Okazaki, O., & Sugiyama, Y. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.25.243 · Cited by 23
Metadata
- Authors
- Bertilsson, L., Lou, Y.-Q., Du, Y.-L., Liu, Y., Kuang, T.-Y., Liao, X.-M., Wang, K.-Y., Reviriego, J., Iselius, L., & Sjöqvist, F.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1992-04
- Volume
- 51
- Issue
- 4
- Pages
- 388-397
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1981202966
- Cited by
- 399
- References
- 0
- FWCI
- 14.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.